SYNCOMFPharmaceuticals
Syncom Formulations India Ltd — Cash Flow Statement
₹10.30
-5.36%
Syncom Formulations India Ltd Cash Flow Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Common Stock Dividend Paid | 0.00 | 0.00 | -2.82 Cr | — | 0.00 |
| Net Common Stock Issuance | 0.00 | 0.00 | 14.58 Cr | 13.63 Cr | — |
| Common Stock Issuance | 0.00 | 0.00 | 14.58 Cr | 13.63 Cr | — |
| Net Issuance Payments Of Debt | -67.90 Cr | -10.69 Cr | 25.39 Cr | -4.30 Cr | — |
| Net Short Term Debt Issuance | -67.90 Cr | -10.69 Cr | 25.39 Cr | -4.30 Cr | — |
| Investing Cash Flow | -18.20 Cr | 83.02 Cr | -44.95 Cr | -27.07 Cr | — |
| Net Other Investing Changes | 15.59 Cr | 14.37 Cr | 14.17 Cr | 9.62 Cr | — |
| Net Investment Purchase And Sale | -23.83 Cr | 76.79 Cr | -38.29 Cr | -25.39 Cr | — |
| Net Investment Properties Purchase And Sale | 0.00 | 0.00 | -0.20 Cr | 0.00 | — |
| Net PPE Purchase And Sale | -9.96 Cr | -8.14 Cr | -20.63 Cr | -11.31 Cr | — |
| Operating Cash Flow | 23.44 Cr | -5.96 Cr | 10.53 Cr | 16.33 Cr | — |
| Taxes Refund Paid | -14.74 Cr | -8.08 Cr | -6.65 Cr | -6.25 Cr | — |
| Change In Working Capital | -16.13 Cr | -28.37 Cr | -3.26 Cr | 3.58 Cr | — |
| Change In Other Current Liabilities | 1.48 Cr | -0.65 Cr | 4.09 Cr | -0.30 Cr | — |
| Change In Other Current Assets | -11.16 Cr | -3.24 Cr | -3.67 Cr | 9.64 Cr | — |
| Change In Payable | 18.65 Cr | 3.70 Cr | 6.66 Cr | -15.51 Cr | — |
| Change In Inventory | -20.25 Cr | 0.12 Cr | -1.69 Cr | 3.05 Cr | — |
| Change In Receivables | -5.41 Cr | -29.30 Cr | -7.41 Cr | 5.05 Cr | — |
| Other Non Cash Items | -15.71 Cr | -8.16 Cr | -10.55 Cr | -9.76 Cr | — |
| Depreciation And Amortization | 5.19 Cr | 4.72 Cr | 4.54 Cr | 3.95 Cr | — |
| Depreciation | 5.19 Cr | 4.72 Cr | 4.54 Cr | 3.92 Cr | — |
| Pension And Employee Benefit Expense | -0.29 Cr | 0.00 | -0.04 Cr | -0.64 Cr | — |
| Gain Loss On Sale Of PPE | 58000.00 | -0.02 Cr | 0.01 Cr | 0.02 Cr | — |
| Net Income From Continuing Operations | 65.51 Cr | 33.98 Cr | 26.56 Cr | 26.15 Cr | — |
| Free Cash Flow | 13.48 Cr | -14.09 Cr | -10.11 Cr | 5.02 Cr | — |
| Issuance Of Capital Stock | 0.00 | 0.00 | 14.58 Cr | 13.63 Cr | — |
| Capital Expenditure | -9.96 Cr | -8.14 Cr | -20.63 Cr | -11.31 Cr | — |
| End Cash Position | 0.71 Cr | 63.38 Cr | 0.88 Cr | 0.30 Cr | — |
| Beginning Cash Position | 63.38 Cr | 0.88 Cr | 0.30 Cr | 2.75 Cr | — |
| Changes In Cash | -62.67 Cr | 62.50 Cr | 0.58 Cr | -2.45 Cr | — |
| Financing Cash Flow | -67.90 Cr | -14.56 Cr | 35.00 Cr | 8.29 Cr | — |
| Net Other Financing Charges | 0.86 Cr | 0.61 Cr | 0.98 Cr | 0.32 Cr | — |
| Interest Paid Cff | -0.86 Cr | -4.47 Cr | -3.13 Cr | -1.36 Cr | — |
| Net Long Term Debt Issuance | — | -10.69 Cr | 25.39 Cr | -4.30 Cr | 59.94 Cr |
| Purchase Of PPE | — | -8.14 Cr | -20.63 Cr | -11.31 Cr | 0.00 |
| Cash Dividends Paid | — | — | -2.82 Cr | — | — |
| Amortization Cash Flow | — | — | 0.03 Cr | 0.03 Cr | 0.03 Cr |
| Other Cash Adjustment Outside Changein Cash | — | — | — | 1000.00 | -1000.00 |
| Purchase Of Investment | — | — | — | — | 0.00 |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Syncom Formulations India Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.